Medpace (MEDP) Economic Moat Analysis31

Moat31

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

structural advantage · 2/4 · Proprietary ClinTrak integrated with SOPs and a broad, multi‑country platform suggest process/know‑how advantages, but there is no direct proof of superior outcomes or stickiness relative to rivals.

durability · 1/4 · Most contracts are terminable on 30 days’ notice and a major competitor reports few industry entry barriers, undermining durability of any edge.

customer dependency · 1/4 · High exposure to small and mid‑sized biopharma customers increases funding and project‑cancellation sensitivity.

erosion resilience · 1/4 · Historical cancellations have negatively impacted results, and low industry entry barriers elevate competitive erosion risk.

Pricing power56

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

realized pricing · 2/4 · Contracts are individually negotiated with upfront fees, but prevalence of fixed/unit pricing and broad termination rights limit ongoing repricing and revenue protection.

retention · 2/4 · Net new business awards increased year over year, indicating healthy demand, but customers can cancel quickly, limiting confidence in long‑term retention.

margin resilience · 3/4 · Reported EBITDA margins remained strong across periods (e.g., 21.7% in Q2 2026 and 24.0% in Q3 2026), supporting resilience despite contract flexibility.

contractual freedom · 2/4 · Flexibility at inception (custom pricing, upfront payments) is offset by fixed/unit fee structures and 30‑day termination provisions.

Predictability99

5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.

Nondeclining revenue years (%)

100.00

Revenue growth volatility (pp)

6.93

Positive FCF years (%)

100.00

FCF margin volatility (pp)

2.79

observedAnnualPeriods

5.00

Financial strength75

Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.

debtFcfGrade

100.00

netDebtEbitGrade

100.00

interestCoverageGrade

100.00

currentRatioGrade

0.00

Debt / FCF (x)

0.00

Net debt / operating income (x)

-0.93

Current ratio (x)

0.74

cashInterestPaid

0.00

Capital allocation—

Missing required inputs: operatingReturn. Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.

3-year average dilution (%)

-3.73

3-year average SBC / revenue (%)

1.22

cashConversionGrade

100.00

Management56

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

capital discipline · 2/4 · Strong operating cash generation alongside significant share repurchases indicates active capital return; value creation versus alternatives is not established.

incentive alignment · 2/4 · NEO stock ownership guidelines at 3x salary and an updated approach to long‑term equity suggest alignment, though actual ownership/vesting performance tests are not detailed.

execution · 3/4 · Revenue grew strongly year over year in Q1 and Q2 2026, demonstrating consistent operational execution.

governance · 2/4 · Governance enhancements include eliminating supermajority voting and granting a stockholder special‑meeting right with a 25%/1‑year threshold.